Advertisement
Advertisement
U.S. markets open in 1 hour 40 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Biocartis Group NV (8XB.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.6690+0.0040 (+0.60%)
As of 08:05AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6650
Open0.6690
Bid0.7000 x 105200
Ask0.7270 x 103100
Day's Range0.6690 - 0.6690
52 Week Range0.4640 - 2.8700
Volume480
Avg. Volume420
Market Cap67.105M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-1.2420
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 8XB.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

      PRESS RELEASE - REGULATED INFORMATION 31 January 2023, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 31 January 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of January 2023 a further portion of receivables due by the Company to Highbridge under the senior secured 'Facility Agreement' (as amended from time to time) ("First Lien Loan Agreement") conclud

    • GlobeNewswire

      Press release Biocartis Group NV: BIOCARTIS MEETS 2022 KEY OBJECTIVES

      PRESS RELEASE: REGULATED INFORMATION17 January 2023, 17:40 CET BIOCARTIS MEETS 2022 KEY OBJECTIVES Mechelen, Belgium, 17 January 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces that the Company has achieved its 2022 key business objectives focused on three performance indicators: Idylla™ product revenues, gross margins on product sales and operating cash burn. Based on non-audited numbers for 2022, Biocar

    • GlobeNewswire

      Press release Biocartis Group NV: Completion of Comprehensive Recapitalization Transactions

      PRESS RELEASE: REGULATED INFORMATION16 January 2023, 17:40 CET Completion of Comprehensive Recapitalization Transactions Mechelen, Belgium, 16 January 2023 –Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART) is pleased to announce that the final steps in the previously announced comprehensive recapitalization transactions have been completed today. The initial holders of the Company's 4.50% new second lien secured convertible

    Advertisement
    Advertisement